[Anticoagulation in patients with chronic renal failure]

Area of Science:

• Nephrology
• Hematology
• Pharmacology

Context:

• Chronic renal failure (CRF) presents challenges for anticoagulation due to altered platelet function and drug metabolism.
• Patients with CRF exhibit impaired clearance of various anticoagulant medications, increasing bleeding risks.
• Platelet dysfunction in CRF can complicate the efficacy and safety of anticoagulant therapies.

Purpose:

• To review the complexities of implementing anticoagulation in patients with chronic renal failure.
• To provide guidance on the appropriate use and monitoring of anticoagulants in renal impairment.
• To highlight the need for cautious dosing and regular laboratory testing for anticoagulated patients with CRF.

Summary:

• Anticoagulation in chronic renal failure (CRF) is challenging due to platelet disorders and impaired drug clearance.
• While heparin and coumarin may not require dose adjustments, frequent coagulation monitoring is essential.
• Low-molecular-weight heparin (LMWH) necessitates cautious long-term use with anti-factor Xa monitoring; a reduced dose is advised for creatinine clearance < 30 ml/mn.
• Danaparoid and thrombin inhibitors are primarily indicated for renal failure patients with heparin-induced thrombocytopenia, requiring regular coagulation tests.

Impact:

• This review aids clinicians in optimizing anticoagulation strategies for patients with chronic renal failure.
• It emphasizes the importance of tailored monitoring and cautious dosing to mitigate risks associated with anticoagulation in CRF.
• Improved understanding can lead to safer and more effective management of thromboembolic disorders in patients with kidney disease.